Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $469.00 at Citigroup
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its price objective lifted by stock analysts at Citigroup from $378.00 to $469.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price target would indicate a potential upside of 37.43% from the company’s […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its price objective lifted by stock analysts at Citigroup from $378.00 to $469.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price target would indicate a potential upside of 37.43% from the company’s […]
